A biotech reckoning: 'We've lost our luster in cell therapies'
A Special Report from the Fierce Biotech team on the state of cell therapy.
Stay updated with breaking news from Vertex Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A Special Report from the Fierce Biotech team on the state of cell therapy.
The deal values each share of Alpine at $65
Vertex Pharmaceuticals will buy Alpine Immune Sciences for about $4.9 billion in cash, gaining access to a treatment for an autoimmune disease of the kidney.
This February 29, a 'rare' date in the stock market calendar, could remain a historic one, for in addition to fairly banal 'monthly highs' and absolute records piling up , this Thursday is marked by a...
Well, it's done: for the past 3 years, the tradition of having an index high coincide - if possible - with the end of the calendar month has been respected.This February 29, which is a rare date in...